CNTA · Centessa Pharmaceuticals
Acquired Company
Eli Lilly acquired Centessa Pharmaceuticals on 6/24/2026 for $38.00 per share in cash plus one non-transferable contingent value right entitling holders to receive up to $9.00 per share in contingent payments.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Market Cap
6.267B
52 Wk Range
$13.22 - $40.56
Previous Close
$40.50
Open
$40.50
Volume
N/A
Day Range
$40.50 - $40.50
Enterprise Value
6.108B
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
0.67%
Institutional Own.
96.93%
Qtr Updated
N/A